Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.

Blood - 1 Jun 2007

Ray Arghya, Cowan-Jacob Sandra W, Manley Paul W, Mestan Jürgen, Griffin James D

Abstract excerpt

Patients with advanced stages of chronic myeloid leukemia (CML) often manifest imatinib mesylate resistance associated with point mutations in BCR-ABL. AMN107 is a new higher-potency inhibitor of BCR-ABL. To identify mutations in BCR-ABL that could result in resistance to AMN107, a cDNA library of BCR-ABL mutants was introduced into Ba/F3 cells followed by selection in AMN107 (0.125-0.5 microM). A total of 86...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutagenesis

Share to Point Mutation

Share to Protein Conformation

Share to Pyrimidines

Source

Identifiers

PMID: 17303698
DOI: 10.1182/blood-2006-01-015347

Genes

BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.PMID 17303698Read ↗

AMN107: tightening the grip of imatinib.Semantic proximity Read ↗

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.Semantic proximity Read ↗

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblSemantic proximity Read ↗

The second generation of BCR-ABL tyrosine kinase inhibitors.Semantic proximity Read ↗

Overriding imatinib resistance with a novel ABL kinase inhibitor.Semantic proximity Read ↗

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.Semantic proximity Read ↗

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.Semantic proximity Read ↗

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitorSemantic proximity Read ↗

The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance ProfileSemantic proximity Read ↗

SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinibSemantic proximity Read ↗

Farnesyl transferase inhibitor resistance probed by target mutagenesis.Semantic proximity Read ↗

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.